R. Barreira-da-silva, M. Laird, N. Yatim, L. Fiette, M. Ingersoll et al., Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy, Nature Immunology, vol.99, issue.8, 2015.
DOI : 10.1038/ni.3201

URL : https://hal.archives-ouvertes.fr/pasteur-01380810

J. Bongers, T. Lambros, M. Ahmad, and E. Heimer, Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs, Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, vol.1122, issue.2, 1992.
DOI : 10.1016/0167-4838(92)90317-7

D. Butera, S. Marukian, A. Iwamaye, E. Hembrador, T. Chambers et al., Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C, Blood, vol.106, issue.4, pp.1175-1182, 2005.
DOI : 10.1182/blood-2005-01-0126

A. Casrouge, J. Decalf, M. Ahloulay, C. Lababidi, H. Mansour et al., Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV, Journal of Clinical Investigation, vol.121, issue.1, pp.308-317, 2011.
DOI : 10.1172/JCI40594DS1

URL : https://hal.archives-ouvertes.fr/pasteur-01402089

A. Casrouge, A. Bisiaux, L. Stephen, M. Schmolz, J. Mapes et al., Discrimination of agonist and antagonist forms of CXCL10 in biological samples, Clinical & Experimental Immunology, vol.110, issue.1, pp.137-148, 2012.
DOI : 10.1111/j.1365-2249.2011.04488.x

URL : https://hal.archives-ouvertes.fr/pasteur-01402047

D. Duffy, R. Mamdouh, M. Laird, C. Soneson, L. Fouler et al., The ABCs of viral hepatitis that define biomarker signatures of acute viral hepatitis, Hepatology, vol.195, issue.4, pp.1273-1282, 2014.
DOI : 10.1002/hep.26901

URL : https://hal.archives-ouvertes.fr/pasteur-01384531

J. Griffith, C. Sokol, and A. Luster, Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity, Annual Review of Immunology, vol.32, issue.1, pp.659-702, 2014.
DOI : 10.1146/annurev-immunol-032713-120145

G. Herman, C. Stevens, V. Dyck, K. Bergman, A. Yi et al., Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses, Clinical Pharmacology & Therapeutics, vol.78, issue.6, pp.675-688, 2005.
DOI : 10.1016/j.clpt.2005.09.002

E. Meissner, J. Decalf, A. Casrouge, H. Masur, S. Kottilil et al., Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy, PLOS ONE, vol.161, issue.9, p.133236, 2015.
DOI : 10.1371/journal.pone.0133236.s001

URL : https://hal.archives-ouvertes.fr/pasteur-01380964

E. Moelants, A. Mortier, J. Van-damme, and P. Proost, In vivo regulation of chemokine activity by post-translational modification, Immunology and Cell Biology, vol.174, issue.6, pp.402-407, 2013.
DOI : 10.1002/1529-0131(200107)44:7<1568::AID-ART280>3.0.CO;2-1

A. Mortier, J. Van-damme, and P. Proost, Regulation of chemokine activity by posttranslational modification, Pharmacology & Therapeutics, vol.120, issue.2, pp.197-217, 2008.
DOI : 10.1016/j.pharmthera.2008.08.006

J. Price, G. Linder, W. Li, B. Zimmermann, K. Rother et al., Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, 2013.

P. Proost, E. Schutyser, P. Menten, S. Struyf, A. Wuyts et al., Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties, Blood, vol.98, issue.13, pp.3554-3561, 2001.
DOI : 10.1182/blood.V98.13.3554

P. Proost, A. Mortier, T. Loos, J. Vandercappellen, M. Gouwy et al., Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration, Blood, vol.110, issue.1, pp.37-44, 2007.
DOI : 10.1182/blood-2006-10-049072

D. Ragab, M. Laird, D. Duffy, A. Casrouge, R. Mamdouh et al., CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients, Cytokine, vol.63, issue.2, pp.105-112, 2013.
DOI : 10.1016/j.cyto.2013.04.016

URL : https://hal.archives-ouvertes.fr/pasteur-01385516

D. Rissin, C. Kan, T. Campbell, S. Howes, D. Fournier et al., Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations, Nature Biotechnology, vol.8, issue.6, pp.595-599, 2010.
DOI : 10.1038/nbt.1641

A. Riva, M. Laird, A. Casrouge, A. Ambrozaitis, R. Williams et al., Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection, Hepatology, vol.22, issue.2, pp.487-496, 2014.
DOI : 10.1002/hep.27139

URL : https://hal.archives-ouvertes.fr/pasteur-01384520

P. Van-den-steen, S. Husson, P. Proost, J. Van-damme, and G. Opdenakker, Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase, Biochemical and Biophysical Research Communications, vol.310, issue.3, pp.889-896, 2003.
DOI : 10.1016/j.bbrc.2003.09.098

K. Van-raemdonck, P. Van-den-steen, S. Liekens, J. Van-damme, and S. Struyf, CXCR3 ligands in disease and therapy, Cytokine & Growth Factor Reviews, vol.26, issue.3, pp.311-327, 2015.
DOI : 10.1016/j.cytogfr.2014.11.009